【主持课题】

[1]. 广东省基础与应用基础研究基金项目：中药配方颗粒临床研究方法学及支持软件研发与应用（编号：2022A1515220162），2022-2024，主持，15万

[2]. 国家自然科学基金面上项目：基于贝叶斯理论构建中医药单病例随机对照试验模型及其临床验证研究，NO: 81774451，2018-2021年，55万，主持

[3]. 广东省自然科学基金：探索适合中医药单病例随机对照试验的数学模型及其临床验证，NO: 2017A030313827，2017-2020年，10万，主持

[4]. 国家自然科学基金青年基金：“基于多维潜变量模型和数据挖掘的溃疡性结肠炎中医证候量化方法学研究”，NO: 81403296，2015-2017年，23万，主持

[5]. 广州中医药大学“薪火计划”资助项目，NO: XH20190102，2019-2021年，10万，主持

[6]. 广东省高等学校优秀青年教师项目（YQ2015041），2016-2018年，30万，主持

[7]. 广州中医药大学“青年英才培养工程”资助项目，NO: QNYC20140101，2015-2018年，20万，主持

[8]. 广州中医药大学“薪火计划”资助项目，NO: XH20140105，2014-2016年，10万，主持

[9]. 广东省医学科研基金：“鼻咽癌患者生存质量量表简短版的研发”，NO: B2013163，2013-2015年，1万，主持

 

【参与课题】

[1]. 国家重点研发计划中医药现代化重点项目：重症肌无力中医诊疗规律系统化研究（编号：2022YFC3501300），2022-2025年（参与）

[2]. 广东省基础与应用基础研究基金：基于DIKW信息融合框架的中药配方颗粒剂不良反应信号机制研究（编号：2021A1515220137），2021-2023年（参与）

[3]. 广东省重点领域研发计划项目：气滞证辨证标准的系统研究（编号：2020B1111100001） 2020-2024年，890万（参与）

[4]. 国家重点基础研究发展计划（973计划）：“中医证候临床辨证的基础研究”子课题“冠心病痰瘀互结证临床表征及其演变规律研究”，NO：2014CB542901，2014-2019年（参加，第八）

[5]. 国家自然科学基金课题：《中医七情量表》研制及其考评的不同定性方法的比较研究，NO: 81774450，2018-2022年，（参加，第三）

[6]. 国家自然科学基金课题：“清化活血法基于microRNA介导SDF-1/CXCR4通路干预BMSCs归巢修复UC的机制研究”，NO: 81503532，2015-2017年，（参加，第四）

[7]. 国家自然科学基金课题：“基于计算机自适应测试和条目反应理论分析的FGIDs辨证诊断模型的方法学研究”，NO:81373786，2014-2017年（参加，第五）

[8]. 国家自然科学基金课题：“脾胃系疾病计算机自适应测试测评体系的临床解释度和属性考评研究”，NO: 81303148，2014-2016年（参加，第六）

[9]. 国家自然科学基金课题：“基于信度效度和项目反应理论的鼻咽癌患者生存质量量表研究及应用”，NO:81272575，2013年（参加，第二）

[10].             国家自然科学基金：“脾胃系疾病患者结局报告的计算机自适应试验信息网络的构建研究”NO:81073163，2011-2013年，（参加，第四）

[11].             国家自然科学基金：“结构方程模型与条目反应理论用于基于辩证的中医功能性胃肠病量表的研究”NO:30873215，2009-2011年，（参加，第二）

[12].             “十一五”国家科技支撑计划课题：“寻常型银屑病中医外治法临床随机对照研究”，NO: 2008BAI53B044，2009-2013年，（参加，第三）

 

【发表的论文】

[1].   Zhou H, Ke J, Liu C, Zhu M, Xiao B, Wang Q, Hou R, Zheng Y, Wu Y, Zhou X, Chen XL(*), Pan H(*). Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis. Front Pharmacol, 2023, 14:1184250. doi: 10.3389/fphar.2023.1184250. (Q1, 5.6)

[2].   Lin W, Liu S, Huang Z, Li H, Lu T, Luo Y, Zhong J, Xu Z, Liu Y, Li Y, Li P, Xu Q, Cai J, Li H, Chen XL(*). Mass cytometry and single-cell RNA sequencing reveal immune cell characteristics of active and inactive phases of Crohn’s disease. Front Med. 2023,9:1064106. doi: 10.3389/fmed.2022.1064106 (Q2, IF=5.058)

[3].         Hou JT, Peng B, Zhang SJ, Luo YX, Chen YM, Cai JZ, Wen Y, Mi H, Luo JF, Zheng XM, Pan SM, Liu SY, Chen XL(*), Chen B(*). The Short Health Scale: A Valid and Reliable Quality-of-Life Scale for Mainland Chinese Patients with Inflammatory Bowel Disease. Palliat Med Rep, 2022, 3(1):154-161. doi: 10.1089/pmr.2021.0066.

[4].         Luo Y, Liu S, Li H, Hou J, Lin W, Xu Z, Lu T, Li Y, Peng B, Zhang S, Han X, Kuang Z, Wen Y, Cai J, Liu F(*), Chen XL(*). Mass Cytometry and Single-Cell Transcriptome Analyses Reveal the Immune Cell Characteristics of Ulcerative Colitis. Front Mol Biosci. 2022;9:859645. IF=6.113

[5].         Luo J, Zhong J, Li H, Zhang S, Zhang L, Hou JT, Ke J, Li H, Liu F(*), Chen XL(*). Translation and evaluation of the simplified Chinese version of the rating form of IBD patient concerns. BMC Gastroenterol. 2022, 22(1):426.

[6].         Hou JT, Peng B, Zhang SJ, Luo YX, Chen YM, Cai JZ, Wen Y, Mi H, Luo JF, Zheng XM, Pan SM, Liu SY, Chen XL(*), Chen B(*). The Short Health Scale: A Valid and Reliable Quality-of-Life Scale for Mainland Chinese Patients with Inflammatory Bowel Disease. Palliat Med Rep, 2022, 3(1):154-161.

[7].         Du J, Tao Q, Liu Y, Huang Z, Jin H, Lin W, Huang X, Zeng J, Zhao Y, Liu L, Xu Q, Han X, Chen L, Chen XL(*), Wen Y(*). Assessment of the targeted effect of Sijunzi decoction on the colorectal cancer microenvironment via the ESTIMATE algorithm. PLoS One. 2022, 17(3):e0264720. (IF: 3.752)

[8].         Chen ZY, Xie DF, Liu ZY, Zhong YQ, Zeng JY, Chen Z(*), Chen XL(*). Identification of the significant pathways of Banxia Houpu decoction in the treatment of depression based on network pharmacology. PLoS One. 2020, 15(9):e0239843. (IF: 3.24)

[9].         Zhou W(#), Zhang S(#), Li HB, Cai Z, Tang S, Chen LX, Lang JY, Chen Z(*), Chen XL(*). Development of Prognostic Indicator Based on Autophagy-Related lncRNA Analysis in Colon Adenocarcinoma. Biomed Res Int. 2020, 2020:9807918. (IF: 2.276)

[10].     Zhou W, Zhang S, Cai Z, Gao F, Deng W, Wen Y, Qiu ZW, Hou ZK, Chen XL(*). A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma. PeerJ. 2020, 8:e9944. (IF: 2.379，Q2)

[11].     Tao Q, Du J, Li X, Zeng JY, Tan B, Xu J, Lin W, Chen XL(*). Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Development and Industrial Pharmacy, 2020, 46(8):1345-1353. (IF: 2.365，Q2，highly cited paper高被引论文)

[12].     Ren Q, Zhou XW, He MY, Fang G, Wang B, Chen XL(*), Li XT(*). A Quantitative Diagnostic Method for Phlegm and Blood Stasis Syndrome in Coronary Heart Disease Using Tongue, Face, and Pulse Indexes: An Exploratory Pilot Study. J Altern Complement Med, 2020, 26(8): 729-737. (IF: 2.109)

[13].     Chen YM, Deng JM, Wen Y, Chen B, Hou JT, Peng B, Zhang SJ, Mi H, Jiang QL, Wu XL, Liu FB(*), Chen XL(*). Modified Sijunzi Decoction in the Treatment of Ulcerative Colitis in the Remission Phase: Study Protocol for a Series of N-of-1 Double-Blind, Randomised Controlled Trials. Trials, 2020, 21(1):396. (IF: 1.883)

[14].     Hou M(#), Zheng Y(#), Ding Z(#), He S, Xu M, Chen X(#), Zhang H(#), Zeng C, Sun C, Jiang W, Wang H, Shen H, Zhang Y, Liu J, Sun S, Jiang N, Cui Y, Sun Y, Chen Y, Cao J, Wang C, Li M, Zhang Y, Wang J, Lin M, Ke Z(*). The role of a semi-automated NanoVelcro system in capturing circulating tumor cells and evaluating their prognostic value for gestational choriocarcinoma. Biomater Sci. 2019, 7(3):1200-1210. doi: 10.1039/c8bm01130c (IF: 6.183，Q1)

[15].     Fang G, Zhang LL, Ren Q, Zhou XW, Wang B, Zhou X, Liu XQ, Peng DH, Chen XL(*), Li XT(*). Development of a Diagnostic Questionnaire for Damp Phlegm Pattern and Blood Stasis Pattern in Coronary Heart Disease Patients (CHD-DPBSPQ). Evid Based Complement Alternat Med. 2019, 2019:6856085.

[16].     Chen XL(*), Wang YM, Zhao F, Chen Z, Yang X, Sun C, Gao Y, Yang TG, Guo T, Chen YM, Zhu SL, Lin XB, Liu FB(*). Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: a meta-analysis. J Gene Med. 2019, 21(9):e3114. (IF: 1.561)

[17].     Chen Z, Cai J, Chen YM, Wei J, Li HB, Lu Y, Zhou Z, Chen XL(*). A meta-analysis of the association between the presence of Helicobacter pylori and periodontal diseases. Medicine (Baltimore). 2019, 98(22):e15922. (IF: 1.87)

[18].     Lin W(#), Chen XL(#), Chen Q, Wen J, Chen X. Jin's three-needle acupuncture technique for chronic fatigue syndrome: a study protocol for a multicentre, randomized, controlled trial. Trials. 2019, 20(1):155. (IF: 1.975)

[19].     Chen XL(#), Liu XQ, Xie R, Peng DH, Wang YP, Zhou X, Wang B, Mo CW, Xu Q, Li X(*). Expert Consensus of Syndrome Differentiation for Phlegm Turbidity Syndrome for Coronary Heart Disease. Evid Based Complement Alternat Med. 2018, 2018: 8184673. (2.064)

[20].     He WL(#), Weng XT, Wang JL, Lin YK, Liu TW, Zhou QY, Hu Y, Pan Y(*), Chen XL(*). Association Between c-Myc and Colorectal Cancer Prognosis: A Meta-Analysis. Frontiers in Physiology, 2018, 9:1549 (3.394，Q1)

[21].     Hou JT(#), Zhao LN(#), Zhang DJ, Lv DY, He WL, Chen B, Li HB, Li PR, Chen LZ, Chen XL(*). Prognostic value of mismatch repair genes for patients with colorectal cancer: meta-analysis. Technol Cancer Res Treat. 2018, 17:1533033818808507. doi: 10.1177/1533033818808507. (1.651)

[22].     Chen XL(#), Wen Y(#), Wu ZC, Zhang BP, Hou ZK, Xiao JL, Lin MQ, Hu Y, Wu ZL, Deng JM, Liu FB(*), Liu TW(*). Development of a Traditional Chinese Medicine Syndrome-Specific Scale for Ulcerative Colitis: The Large Intestine Dampness-Heat Syndrome Questionnaire. Evid Based Complement Alternat Med. 2018, 2018:4039019. (2.064)

[23].     Chen XL(#*), Zhong LH(#), Wen Y, Liu TW, Li XY, Hou Zk, Hu Y, Mo CW, Liu FB(*). Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties. Health Qual Life Out, 2017, 15:177. (IF: 2.1514，Q2)

[24].     Chen XL, Mo CW, Lu LY, Gao RY, Xu Q, Wu MF, Zhou QY, Hu Y, Zhou X, Li XT(*). Methological Quality of Systematic Reviews and Meta-Analyses on Acupuncture for Stroke: A Review of Review. Chin J Integr Med, 2017, 23(11):871-877. (IF: 1.116)

[25].     Huang CY(#), Zhou QY(#), Hu Y, Wen Y, Qiu ZW, Liang MG, Mo JL, Xu JH, Sun C, Liu FB(*), Chen XL(*). Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis. Oncotarget, 2017, 8(14): 23459-23469 (IF: 5.168)

[26].     Chen XL(#), Chen ZQ(#), Zhu SL, Liu TW, Wen Y, Su YS, Xi XJ, Hu Y, Lian L(*), Liu FB(*). Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: a meta-analysis. BMC Cancer, 2017, 17(1):240. (IF: 3.265，Q2)

[27].     Chen XL(#), She SF(#), Li YH, Zhang WJ, Tang YT, Zhuang KH, Pan YB(*), Liu FB(*), He WL(*). Azathioprine/6-mercaptopurine versus 5-aminosalicylic for treatment of inflammatory bowel disease. Int J Clin Exp Med, 2017, 10(2):1927-1936 (IF: 1.075)

[28].     Su Y(#), Mo CW(#), Cheng WQ, Wang L, Xu Q, Wu ZC, Wu ZL, Liu LZ, Chen XL(*). Development and validation of quality of life scale of nasopharyngeal carcinoma patients: The QOL-NPC (version 2). Health Qual Life Out, 2016, 14:76. (IF: 2.143，Q2)

[29].     Chen X(#), Hou J(#), Yuan Y, Huang C, Liu T, Mo C, Li H, Chen B, Xu Q, Hou Z, He W(*), Liu F(*). Adalimumab for moderately to severely active ulcerative colitis: A systematic review and meta-analysis. Biodrugs, 2016, 30(3):207-217 (IF: 2.835，Q2)

[30].     Zhang J(#), Gao F(#), Yang A, Chen W, Chen S, Li H, Zhang X, Yang Z, Chen X (*), Song M (*). Epidemiologic characteristics of oral cancer: single-center analysis of 4097 patients from the Sun Yat-sen University Cancer Center. Chinese Journal of Cancer, 2016, 35(1):24. doi: 10.1186/s40880-016-0078-2 (IF: 4.111)

[31].     He W(#), Tu J(#), Huo Z, Li Y, Peng J, Qiu Z, Luo D, Ke Z(*), Chen X(*). Surgical interventions for gastric cancer: a review of systematic reviews. Int J Clin Exp Med, 2015, 8(8):13657-13669. (IF: 1.277)

[32].     Chen XL(#), Qiu ZW(#), Gu MF(*), Su Y, Liu LZ(*), Liu Y, Mo CW, Xu Q, Sun J, Li DH. Translation and validation of the Chinese version of the quality of life radiation therapy instrument and the head & neck module (QOL-RTI/H&N). Health Qual Life Out, 2014, 12:51.(IF: 2.12，Q2)

[33].     Chen X, Chen P(*). A Comparison of Four Methods for the Analysis of N-of-1 Trials. PLOS ONE, 2014, 9(2):e87752. doi: 10.1371/journal.pone.0087752. (IF: 3.234，Q1)

[34].     He W(#), Li Y(#), Chen X(#), Lu L, Tang B, Wang Z, Pan Y, Cai S, He Y(*), Ke Z(*). miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J GASTROEN HEPATOL. 2014, 29(7):1427-34. (IF:3.504，Q2)

[35].     Gu MF(#), Su Y(#), Chen XL(#*), He WL, He ZY, Li JJ, Chen MQ, Mo CW, Xu Q, Diao YM. Quality of life and radiotherapy complications of Chinese nasopharyngeal carcinoma patients at different 3DCRT stage, Asian Pacific Journal of cancer prevention, 2012, 13(1):75-79 (IF:1.271)

[36].     Chen MY, Qiu ZW, Tang HM, Zhuang KH, Cai QQ, Chen XL(*), Li HB(*). Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis. Medicine (Baltimore). 2019 98(47):e17955. (IF: 1.87)

[37].     Hu Y(#), Tao SY(#), Deng JM, Hou ZK, Liang JQ, Huang QG, Li LH, Li HB, Chen YM, Yi H, Chen XL(*), Liu H(*). Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2018, 19(11):3001-3008.

[38].     Li HB(#), Chen MY(#), Qiu ZW, Cai QQ, Li DT, Tang HM(*), Chen XL(*). Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis. Medicine (Baltimore). 2018, 97(21):e10807. (2.028)